Benefit of early treatment in inflammatory polyarthritis patients with anti–cyclic citrullinated peptide antibodies versus those without antibodies

Lignende værker

• Association of a rheumatoid arthritis susceptibility variant at the CCL21 locus with premature mortality in inflammatory polyarthritis patients
  af: Farragher, Tracey M, et al.
  Udgivet: (2010)
• Long-term stability of anti-cyclic citrullinated peptide antibody status in patients with early inflammatory polyarthritis
  af: Burr, Marian L, et al.
  Udgivet: (2012)
• Association of Functional Outcome With Both Personal- and Area-Level Socioeconomic Inequalities in Patients With Inflammatory Polyarthritis
  af: Harrison, Mark J, et al.
  Udgivet: (2009)
• The role of rheumatoid arthritis genetic susceptibility markers in the prediction of erosive disease in patients with early inflammatory polyarthritis: results from the Norfolk Arthritis Register
  af: Plant, Darren, et al.
  Udgivet: (2011)
• The performance of anti–cyclic citrullinated peptide antibodies in predicting the severity of radiologic damage in inflammatory polyarthritis: Results from the Norfolk Arthritis Register
  af: Bukhari, M, et al.
  Udgivet: (2007)